Leukemia Panel-AML Mutation, Blood

Mutations in the FLT3, NPM1, and CEBPA genes play a crucial role in the development and progression of acute myelogenous leukaemia (AML). The Leukemia Panel-AML Mutation test, performed on blood samples, is designed to detect mutations in the FLT3, NPM1, and CEBPA genes. The assay focuses on these specific genes as they have clinical utility in risk stratification for patients with newly diagnosed cytogenetically normal acute myelogenous leukemia (CN-AML). CN-AML refers to cases where standard cytogenetic analysis does not reveal any chromosomal abnormalities. By analyzing mutations in FLT3, NPM1, and CEBPA, the Leukemia Panel-AML Mutation test aids in determining the risk profile and prognosis for individuals with CN-AML. Mutations in FLT3, such as internal tandem duplications (ITD), are associated with a poor prognosis, while NPM1 and CEBPA mutations are considered favorable prognostic markers. This information helps healthcare professionals in making informed treatment decisions and selecting appropriate therapeutic strategies for CN-AML patients, ultimately improving patient outcomes.